- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01842477
Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing (OrthoCT1)
Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing in Patients With Delayed Consolidation After Long Bone Fracture Requiring Graft Apposition or Alternative Orthobiologics
Bone grafting is widely used in hospitals to repair injured, aged or diseased skeletal tissue. In Europe, about one million patients encounter a surgical bone reconstruction annually and the numbers are increasing due to our ageing population. Bone grafting intends to facilitate bone healing through osteogenesis (i.e. bone generation) at the site of damage, but this is only attained presently by including cells capable of forming bone into the augmentation.
Bone autograft is the safest and most effective grafting procedure, since it contains patient's own bone growing cells (to enhance osteogenesis) and proteins (to enhance osteoinduction), and it providing a scaffold for the new bone to grow into (osteoconduction). However, bone autograft is limited in quantity (about 20 cc) and its harvesting (e.g. from the iliac crest) represents an additional surgical intervention, with frequent consequent pain and complications.
We hypothesize that using autologous bone marrow cells expanded in GMP facility surgically implanted with synthetic bone substitutes contribute to the resolution of the health and socioeconomic complications of delayed union or non-union after diaphyseal and metaphyseal-diaphyseal fractures with safety and efficacy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Tissue engineering combines bone marrow cells or mesenchymal stem cells (MSCs), synthetic scaffolds and molecular signals (growth or differentiating factors) in order to form hybrids constructs. For bone reconstruction purposes, human MSCs have been seeded and cultured on porous calcium phosphate ceramics in osteogenic media. Some clinical studies with low numbers of patients have been reported using this approach but the outcomes were inconsistent with low efficacy in bone regeneration. The reasons of the limited clinical success may be due to several bottlenecks in the multidisciplinary field of bone tissue engineering. The association in vitro of biomaterials and osteoprogenitor cells raises technical challenges and regulatory and ethic issues for the implementation of clinical trials, whereas the expansion of MSCs is now possible in GMP Facility.
The expected results are to obtain bone consolidation thus healing of delayed union or non-union, as proven by imaging techniques, without using bone graft. This will prove the efficacy of the proposed IMP based on pluripotent MSCs expanded in a GMP facility and mixed with granulated biphasic calcium phosphate in the surgical setting before implantation. No expected complications related to the procedure are expected. Changes in serum levels of bone turnover markers will be described.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Créteil, France, 94000
- Depatment of Orthopaedic Surgery, Hôpital Henri Mondor
-
Tours, France, 37044
- Department of Orthopaedic Surgery, CHRU Tours
-
-
-
-
-
Ulm, Germany, 89081
- Department of Orthopaedic Trauma, University of Ulm
-
-
-
-
-
Bologna, Italy, 40136
- Istituto Ortopedico Rizzoli, Bologna
-
-
-
-
-
Madrid, Spain, 28046
- Servicio de Cirugía Ortopédica y Traumatología "A", Hospital La Paz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 65, both sexes
- Traumatic isolated closed or open Gustilo I and II humerus, tibial or femur diaphyseal or metaphyseal-diaphyseal fracture status delayed union or non-union
- At least 3 months from acute fracture
- Able to provide informed consent, and signed informed consent
- Patients (by themselves) should have medical health care coverage to be included in a research study
- Able to understand and accept the study constraints
Exclusion Criteria:
- Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
- Participation in another therapeutic trial in the previous 3 months
- Delayed union or non-union related to iatrogeny
- Segmental bone loss requiring specific therapy (bone transport, large structural allograft, megaprosthesis, etc)
- Vascular or neural injury
- Other fractures causing interference with weight bearing
- Acute persistent chronic bacterial infections such as brucellosis, typhus, leprosy, relapsing fever, melioidosis and tularemia
- Visceral injuries of diseases interfering with callus formation (cranioencephalic trauma, etc.)
- History of bone harvesting on iliac crest contraindicating bone-marrow aspiration
- Corticoid or immunosuppressive therapy more than one week in the three months prior to study inclusion
- History of prior or concurrent diagnosis of HIV-, Syphilis, Hepatitis-B- or Hepatitis-C-infection (confirmed by serology or PCR)
- History of neoplasia or current neoplasia in any organ
- Subject legally protected, under legal guardianship, deprived of their liberty by judicial or administrative decision, subject of psychiatric care, or admission to a health facility.
- Impossibility to meet at the appointments for the follow up
- Insulin dependent diabetes
- Obesity (BMI > 30)
- Autoimmune inflammatory disease
- Current treatment by biphosphonate or stopped in the three months prior to study inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Implantation surgery
All the patients will have the implantation surgery.
This trial is a one-arm study.
|
Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up
Time Frame: At 6 weeks, 12 weeks, 24 weeks and 52 weeks after the implantation surgery
|
At 6 weeks, 12 weeks, 24 weeks and 52 weeks after the implantation surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with proven bone healing
Time Frame: 6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
Amount of radiological callus
Time Frame: 6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
Clinical consolidation
Time Frame: 6 weeks, 12 weeks, and 24 weeks after implantation surgery
|
6 weeks, 12 weeks, and 24 weeks after implantation surgery
|
No reoperation done or scheduled
Time Frame: 24 weeks after implantation surgery
|
24 weeks after implantation surgery
|
Changes in serum levels of bone turnover markers
Time Frame: 6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
6 weeks, 12 weeks, and 24 weeks after the implantation surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Enrique Gomez Barrena, Universidad Autonoma de Madrid
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C11-12
- 2011-005441-13 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delayed Union After Fracture of Humerus, Tibial or Femur
-
University of LouisvilleRecruitingTibial Fractures | Nonunion of Fracture | Delayed Union of FractureUnited States
-
Synthes GmbHSynthes Australia Pty LtdWithdrawnProximal or Diaphyseal Humerus Fracture | Diaphyseal or Distal Femur Fracture | Diaphyseal, Distal or Proximal Tibia FractureAustralia
-
AO Clinical Investigation and Publishing DocumentationSynthes Inc.CompletedHumerus Fracture | Femur Fracture | Tibia FractureAustria, Germany
-
Beth Israel Deaconess Medical CenterWithdrawnHumerus Fracture | Femur Fracture | Tibia FractureUnited States
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...CompletedFracture | Delayed Union of FractureChina
-
The University of Hong KongRecruitingProximal Humeral Fracture | Distal Humerus Fracture | Distal Femur Fracture | Distal Tibia FractureHong Kong
-
Balgrist University HospitalUniversity of ZurichTerminatedFracture of Clavicle | Fracture of Femur | Fracture of Humerus | Fracture of Ulna Radius | Fracture of Hand | Fracture of Pelvis | Fracture of Tibia Fibula | Fracture of SkullSwitzerland
-
LifeNet HealthRecruitingFractures, Bone | Nonunion of Fracture | Fractures, Ununited | Fractures, Open | Fracture of Femur | Fracture, Tibial | Fracture ArmUnited States
-
McGill University Health Centre/Research Institute...CompletedMalunion of Fracture of Clavicle | Delayed Union of Fracture of ClavicleCanada
-
Cedars-Sinai Medical CenterStryker NordicCompletedTibial Fractures | Nonunion of Fracture | Femur Fracture | Tibia Fracture | Nonunion of Fracture of Tibia | Nonunion of Fracture of Femur (Diagnosis)United States
Clinical Trials on Implantation of bone substitute plus autologous cultured mesenchymal cells
-
Universidad Autonoma de MadridCompletedAvascular Necrosis of the Femoral HeadItaly, France, Germany, Spain
-
Universidad Autonoma de MadridActive, not recruitingNon Union FractureFrance, Spain, Germany, Italy
-
Hadassah Medical OrganizationTeva Branded Pharmaceutical Products R&D, Inc.Completed
-
Hadassah Medical OrganizationCompletedMultiple Sclerosis
-
Assiut UniversityUnknownStem Cell Transplant Complications
-
Clinica Universidad de Navarra, Universidad de...CompletedIdiopathic Pulmonary FibrosisSpain
-
Aderans Research InstituteCompletedAndrogenetic Alopecia | Male Pattern Baldness | Female Pattern BaldnessUnited States
-
Germans Trias i Pujol HospitalMinisterio de Sanidad, Servicios Sociales e IgualdadCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Spain
-
TCA Cellular TherapySuspendedSpinal Cord InjuryUnited States
-
Leiden University Medical CenterCompleted